Gemcitabine elaidate and ONC201 combination therapy for inhibiting pancreatic cancer in a KRAS mutated syngeneic mouse model
Abstract Approximately 90% of pancreatic cancer (PC) contain KRAS mutations. Mutated KRAS activates the downstream oncogenic PI3K/AKT and MEK signaling pathways and induces drug resistance. However, targeting both pathways with different drugs can also lead to excessive toxicity. ONC201 is a dual PI...
Main Authors: | Virender Kumar, Bharti Sethi, Dalton W. Staller, Prakash Shrestha, Ram I. Mahato |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2024-03-01
|
Series: | Cell Death Discovery |
Online Access: | https://doi.org/10.1038/s41420-024-01920-9 |
Similar Items
-
Palmitoyl Carnitine-Anchored Nanoliposomes for Neovasculature-Specific Delivery of Gemcitabine Elaidate to Treat Pancreatic Cancer
by: Akanksha Patel, et al.
Published: (2022-12-01) -
Effects of Elaidic Acid on HDL Cholesterol Uptake Capacity
by: Takuya Iino, et al.
Published: (2021-09-01) -
Pancreatic Cancer Chemoresistance to Gemcitabine
by: Manoj Amrutkar, et al.
Published: (2017-11-01) -
Development of a syngeneic mouse model of epithelial ovarian cancer
by: Quinn Bridget A, et al.
Published: (2010-10-01) -
Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model
by: Concetta Panebianco, et al.
Published: (2023-04-01)